Return to List

Study Summary
No. 2007-0509:.......Ovary......Diane C. Bodurka......Gynecologic Oncology
.
Study Summary Title
Study Summary
Number:		2007-0509
Study Title:An Ancillary Study of Patients with Advanced Stage Serous Carcinoma of the Ovary Treated on GOG Protocol 158: A Survival Analysis Based on Reclassification to a Two-tier Grading System
.
Physician New Patient Referral
Name:Diane C. BodurkaPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Gynecologic OncologyReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-745-3358
Contact us about clinical trials
.
General Information
Disease Group:OvarySupported By:Gynecologic Oncology Group
Phase of Study:N/AReturn
Visit:		N/A
Treatment
Agents:		NoneHome Care:N/A
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		N/A
Description/
Intervention:		Unavailable
.
Study Objectives / Outcomes
Primary Objective:
To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system.

Secondary Objective:
To determine the overall and progression-free survival of patients with serous carcinoma of the ovary treated on GOG protocol 158 when reclassified according to tumor grade (low vs. high).

Tertiary Objective:
To correlate histologic grade with other prognostic factors.
.
Study Status Information
Study Activation / Registration Date:08/07/2007
IRB Review and Approval Date:08/26/2008
Study Type:Other
Recruitment Status:Closed
Projected Accrual:N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:1) All patients enrolled on GOG protocol 158 with a diagnosis of serous carcinoma of the ovary.
Exclusion Criteria:N/A
.
Links
Registration Number: NCT00837993
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center